# PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver Metastases

> **NCT06519266** · PHASE3 · RECRUITING · sponsor: **Vastra Gotaland Region** · enrollment: 40 (estimated)

## Conditions studied

- Uveal Melanoma
- Liver Metastases

## Interventions

- **DEVICE:** PHP
- **DRUG:** IPI1/NIVO3
- **DRUG:** IPI3/NIVO1

## Key facts

- **NCT ID:** NCT06519266
- **Lead sponsor:** Vastra Gotaland Region
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-10
- **Primary completion:** 2028-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06519266

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06519266, "PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver Metastases". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06519266. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*